Just parking a couple of bits of old stuff -
Licence obligations (other than DRC) -
CAT pays the MRC royalties of 3% of the net invoice price on the sale by CAT of products made using the patent rights and technology licensed under this agreement. Where CAT's sub-licensees sell such products, CAT is obligated to pay the MRC between 1% and 2.3% of the net invoice price, calculated in accordance with a specified formula. The royalty obligations of CAT may be reduced under certain circumstances.
CAT's license with the MRC includes the Winter II, McCafferty and Griffiths patent families, which are described below. CAT also has a non-exclusive license from Dyax Corporation ("Dyax") for rights under certain Dyax patents relating to phage display. CAT will pay royalties to Dyax Corporation on the sale of products made using relevant technology.
CAT has licensed intellectual property relating to the use of certain inhibitors of TGFa (for prevention of fibrosis) from the Burnham Institute and Integra Life Sciences Corporation. CAT's license is exclusive, royalty
bearing and worldwide and allows CAT to make, use and sell certain products which incorporate the intellectual property; it also provides for CAT to pay to the
Burnham Institute and Integra a proportion of any up front, milestone or similar payments received in relation to the intellectual property.
The use of CAT-152 and CAT-192 for the prevention and treatment of fibrosis fall within the terms of this license from the Burnham Institute and Integra.
Other patents -
In connection with its 1998 acquisition of Aptein, CAT acquired patents covering ribosome display technology, under which human monoclonal antibodies can be displayed in a laboratory environment without the use of a phage. CAT
is conducting research and development activities involving this technology.
These patents have been issued in Australia, Europe and South Korea, which expire in 2010, and in the United States, which expire in 2011. Patent applications are pending in Japan, which, if issued, would expire in 2010. |
